Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group. Goldstein D, et al. Among authors: spry n. Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1. Br J Cancer. 2012. PMID: 22134511 Free PMC article. Clinical Trial.
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, Shapiro J, Davies T, Reece W, Harvey J, Spry N. Goldstein D, et al. Among authors: spry n. Br J Cancer. 2007 Aug 20;97(4):464-71. doi: 10.1038/sj.bjc.6603900. Epub 2007 Jul 24. Br J Cancer. 2007. PMID: 17653074 Free PMC article. Clinical Trial.
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D. Spry N, et al. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1438-46. doi: 10.1016/j.ijrobp.2007.08.070. Epub 2007 Dec 31. Int J Radiat Oncol Biol Phys. 2008. PMID: 18164859 Clinical Trial.
Chemotherapy for pancreatic cancer.
Bydder S, Spry N. Bydder S, et al. Among authors: spry n. N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5. N Engl J Med. 2004. PMID: 15218576 No abstract available.
Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer--toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study.
Denham JW, Hamilton CS, Christie D, O'Brien M, Bonaventura A, Stewart JF, Ackland SP, Lamb DS, Spry NA, Dady P, et al. Denham JW, et al. Among authors: spry na. Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):305-13. doi: 10.1016/0360-3016(94)E0065-R. Int J Radiat Oncol Biol Phys. 1995. PMID: 7836084 Clinical Trial.
228 results